See the DrugPatentWatch profile for brexanolone
Brexanolone, approved for treating postpartum depression, has its patent information and related data tracked by Drugpatentwatch. This includes details about its patent status and any potential challenges or expirations [1].
When does brexanolone's exclusivity expire?
The exclusivity period for brexanolone is tied to its patent protections. Drugpatentwatch monitors these patents to provide insights into when market exclusivity might end, which could open doors for generic or biosimilar competition [1].
Who is developing brexanolone?
The drug brexanolone is associated with Sage Therapeutics, Inc. [2].
How does brexanolone work?
Brexanolone is a neuroactive steroid that acts as a positive allosteric modulator of GABAA receptors [3]. It is administered as a continuous intravenous infusion [3].
What are the clinical findings for brexanolone?
Clinical trials for brexanolone demonstrated a rapid and significant reduction in depressive symptoms in women with postpartum depression [3]. Data showed that patients treated with brexanolone experienced a greater decrease in their Hamilton Depression Rating Scale (HAM-D) scores compared to placebo [3].
What are the risks associated with brexanolone?
The primary safety concern identified with brexanolone is excessive sedation, which can lead to a loss of consciousness [3]. Due to this risk, patients must be monitored continuously during administration, and the infusion must be stopped if excessive sedation occurs [3].
Can brexanolone be used for other conditions?
While brexanolone is approved for postpartum depression, its mechanism of action, related to GABAA receptor modulation, suggests potential for other neurological or psychiatric conditions. However, current approvals and extensive public data are focused on its use in postpartum depression [1, 3].